Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan
Shire Announces FDA Approval of TAKHZYRO (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
New Drug Application Submitted in Japan for INTUNIV (guanfacine hydrochloride extended release) in Adults with ADHD
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth
Apex Commences Drilling at Jersey Emerald Property and Announces Amendment to Terms of Lithium Creek Option Agreement
